1 Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Key Questions Answered in This Report
1.3 Research Methodology
1.3.1 Global FLT3 inhibitors Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Market Overview
1.4.1 Introduction
1.4.2 Current Market Size and Growth Potential, $Million, 2021-2032
1.4.3 Types of FLT3 Gene Mutations Involved in AML
1.4.3.1 FLT3-ITD Mutation
1.4.3.2 FLT3-TKD Mutation
1.4.4 Mechanism of FLT3 Inhibitors
1.4.5 Classification of FLT3 Inhibitors
1.4.6 Resistance to AML Therapy Targeted at FLT3
1.4.7 Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.7.1 Global Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.7.2 North America Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.7.3 Europe Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.7.4 China Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.7.5 Japan Epidemiology of FLT3 Mutated Acute Myeloid Leukemia
1.4.8 Role of Companion Diagnostics in FLT3 Inhibitors Market
1.4.8.1 Drug-Diagnostic Co-Development
1.4.8.2 Companion Diagnostic Tests for FLT3 Mutated Acute Myeloid Leukemia
1.4.8.2.1 LeukoStrat CDx FLT3 Mutation Assay
1.4.8.2.2 Dovitinib DRP Companion Diagnostic
1.4.9 Pipeline Analysis
1.4.9.1 By Clinical Phase
2 Industry Analysis
2.1 Overview
2.2 Legal Requirements and Frameworks in the U.S.
2.2.1 Clinical Trial Authorization
2.2.2 Marketing Authorization
2.2.3 Post-Authorization Regulations
2.3 Legal Requirements and Frameworks in Europe
2.4 Legal Requirements and Frameworks in Japan
2.5 Reimbursement and Cost Analysis
2.5.1 U.S.
2.5.2 Europe
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Increasing Incidence of Acute Myeloid Leukemia
3.3.2 Introduction of Novel Products
3.3.3 Rising Research and Development Investments
3.4 Market Restraints
3.4.1 High Treatment Cost Impacting the Adoption Rate
3.4.2 Disease Relapse in FLT3 Mutated AML
3.5 Market Opportunities
3.5.1 Massive Scope in Emerging Markets
4 Competitive Landscape
4.1 Overview
4.2 Key Developments and Strategies
4.2.1 Regulatory and Legal Activities
4.2.2 Product Approvals and Launches
4.2.3 Partnerships and Alliances
4.2.4 Other Developments
4.3 Market Share Analysis (by Company), 2021
4.4 Growth-Share Analysis
5 Global FLT3 inhibitors Market (by Commercialized Therapies), $Million, 2021-2032
5.1 Overview
5.2 Type 1 FLT3 Inhibitors
5.2.1 Xospata (Gilteritinib)
5.2.2 Rydapt (Midostaurin)
5.3 Type 2 FLT3 Inhibitors
5.3.1 Vanflyta (Quizartinib)
6 Global FLT3 inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032
6.1 Overview
6.2 Crenolanib
6.2.1 Crenolanib for Indication 1 (Newly Diagnosed FLT3 Mutated AML)
6.2.1.1 Safety and Efficacy Results of Crenolanib for Newly Diagnosed FLT3 Mutated AML
6.2.2 Crenolanib for Indication 2 (Relapsed/Refractory FLT3 Mutated AML)
6.2.2.1 Safety and Efficacy Results of Crenolanib for Relapsed/Refractory FLT3 Mutated AML
6.3 Dovitinib
6.3.1 Safety and Efficacy Results of Dovitinib for Metastatic Renal Cell Carcinoma
6.4 SKLB1028
7 Global FLT3 inhibitors Market (by Region), $Million, 2021-2032
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.1.1 Commercialized Products
7.2.1.2 Market Size and Forecast
7.2.2 Canada
7.2.2.1 Commercialized Products
7.2.2.2 Market Size and Forecast
7.3 Europe
7.3.1 Germany
7.3.1.1 Market Size and Forecast
7.3.2 Italy
7.3.2.1 Market Size and Forecast
7.3.3 France
7.3.3.1 Market Size and Forecast
7.3.4 U.K.
7.3.4.1 Market Size and Forecast
7.3.5 Spain
7.3.5.1 Market Size and Forecast
7.3.6 Rest-of-Europe
7.3.6.1 Market Size and Forecast
7.4 Asia-Pacific
7.4.1 Japan
7.4.1.1 Commercialized Products
7.4.1.2 Market Size and Forecast
7.4.2 China
7.4.2.1 Commercialized Products
7.4.2.2 Market Size and Forecast
7.4.3 Rest-of-Asia-Pacific
7.4.3.1 Market Size and Forecast
7.5 Rest-of-the-World
8 Company Profiles
8.1 Overview
8.2 Cullinan Oncology, LLC
8.2.1 Company Overview
8.2.2 Role of Cullinan Oncology, LLC in the Global FLT3 inhibitors Market
8.2.3 Key Competitors of the Company
8.2.4 Key Insights about Financial Health of the Company
8.2.5 Recent Developments
8.2.6 Analyst’s Perspective
8.3 Astellas Pharma Inc.
8.3.1 Company Overview
8.3.2 Role of Astellas Pharma Inc. in the Global FLT3 inhibitors Market
8.3.3 Key Competitors of the Company
8.3.4 Financials
8.3.5 Key Insights about Financial Health of the Company
8.3.6 Recent Developments
8.3.7 Analyst’s Perspective
8.4 Allarity Therapeutics, Inc.
8.4.1 Company Overview
8.4.2 Role of Allarity Therapeutics, Inc. in the Global FLT3 inhibitors Market
8.4.3 Key Competitors of the Company
8.4.4 Recent Developments
8.4.5 Analyst’s Perspective
8.5 AROG Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Role of AROG Pharmaceuticals, Inc. in the Global FLT3 inhibitors Market
8.5.3 Key Competitors of the Company
8.5.4 Analyst’s Perspective
8.6 Aptose Biosciences Inc.
8.6.1 Company Overview
8.6.2 Role of Aptose Biosciences Inc. in the Global FLT3 inhibitors Market
8.6.3 Key Competitors of the Company
8.6.4 Key Insights about Financial Health of the Company
8.6.5 Recent Developments
8.6.6 Analyst’s Perspective
8.7 Novartis International AG
8.7.1 Company Overview
8.7.2 Role of Novartis International AG in the Global FLT3 inhibitors Market
8.7.3 Key Competitors of the Company
8.7.4 Financials
8.7.5 Key Insights about Financial Health of the Company
8.7.6 Analyst’s Perspective
8.8 Daiichi Sankyo Company, Limited
8.8.1 Company Overview
8.8.2 Role of Daiichi Sankyo Company, Limited. in Global FLT3 inhibitors Market
8.8.3 Key Competitors of the Company
8.8.4 Financials
8.8.5 Key Insights about Financial Health of the Company
8.8.6 Recent Developments
8.8.7 Analyst’s Perspective
8.9 CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
8.9.1 Company Overview
8.9.2 Role of CSPC ZhongQi Pharmaceutical Technology Co., Ltd. in the Global FLT3 Inhibitors Market
8.9.3 Key Competitors of the Company
8.9.4 Financials
8.9.5 Key Insights about Financial Health of the Company
8.9.6 Analyst’s Perspective
8.1 FUJIFILM Pharmaceuticals U.S.A., Inc.
8.10.1 Company Overview
8.10.2 Role of FUJIFILM Pharmaceuticals U.S.A., Inc. in the Global FLT3 Inhibitors Market
8.10.3 Key Competitors of the Company
8.10.4 Analyst’s Perspective
8.11 Jiangsu HengRui Medicine Co., Ltd.
8.11.1 Company Overview
8.11.2 Role of Jiangsu HengRui Medicine Co., Ltd. in the Global FLT3 Inhibitors Market
8.11.3 Key Competitors of the Company
8.11.4 Financials
8.11.5 Key Insights about Financial Health of the Company
8.11.6 Analyst’s Perspective
List of Figures
Figure 1: FLT3 Inhibitors Approved by U.S. Food and Drug Administration (FDA), 2015-2021
Figure 2: FLT3 Inhibitors Global Clinical Trials (by Phase)
Figure 3: Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032
Figure 4: Global FLT3 Inhibitors Market: Impact Analysis of Market Drivers and Restraints
Figure 5: Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032
Figure 6: Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032
Figure 7: Global FLT3 inhibitors Market Segmentation
Figure 8: Global FLT3 inhibitors Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Step by Step Approach
Figure 12: Global FLT3 Inhibitors Market, $Million, 2021-2032
Figure 13: FLT3 Gene Mutations in AML Patients
Figure 14: Classification of FLT3 Inhibitors
Figure 15: Common and Notable Toxicities Associated with FLT3 Inhibitors
Figure 16: Estimated Global Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2021-2032
Figure 17: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in North America, 2021-2032
Figure 18: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Europe, 2021-2032
Figure 19: Percentage of FLT3 Mutated Acute Myeloid Leukemia Prevalence (by Country), 2021
Figure 20: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in China, 2021-2032
Figure 21: Estimated Prevalence and Incidence of FLT3 Mutated Acute Myeloid Leukemia in Japan, 2021-2032
Figure 22: Drug Diagnostic Co-Development Model
Figure 23: FLT3 Inhibitors Emerging Therapies: Developmental Phases
Figure 24: Clinical Trial Authorization for FLT3 Inhibitors
Figure 25: Process for Obtaining Marketing Authorization
Figure 26: Procedures Offered by the Food and Drug Administration (FDA) for Drugs Intended to Treat Serious Health Conditions
Figure 27: U.S. Food and Drug Administration Review Timeline
Figure 28: EMA Review Timeline
Figure 29: Current Reimbursement Scenario in Europe
Figure 30: Global Incidence of Acute Myeloid Leukemia, 2015-2019
Figure 31: Global Incidence of FLT3 Mutated Acute Myeloid Leukemia, 2016-2020
Figure 32: Number of Clinical Trials for FLT3 Inhibitors (by Major Player)
Figure 33: Mechanisms Responsible for Resistance to FLT3 Inhibitors
Figure 34: Clinical Strategies to Overcome Drug Resistance in FLT3-ITD AML
Figure 35: Share of Key Developments and Strategies, January 2019-June 2022
Figure 36: Regulatory and Legal Activities (by Company), January 2019-June 2022
Figure 37: Product Approvals and Launches (by Company), January 2019-June 2022
Figure 38: Partnerships and Alliances (by Company), January 2019-June 2022
Figure 39: Market Share Analysis of the Global FLT3 Inhibitors market (by Company), 2021
Figure 40: Growth-Share Matrix for the Global FLT3 inhibitors Market (by Company), 2021
Figure 41: Global FLT3 Inhibitors Market (by Commercialized Therapies), $Million, 2021-2032
Figure 42: Global FLT3 Inhibitors Market (by Type 1 FLT3 Inhibitors), $Million, 2021-2032
Figure 43: Global FLT3 Inhibitors Market (Xospata, by Type 1 FLT3 Inhibitors), $Million, 2021-2032
Figure 44: Global FLT3 Inhibitors Market (Rydapt, by Type 1 FLT3 Inhibitors), $Million, 2021-2032
Figure 45: Global FLT3 Inhibitors Market (Vanflyta, by Type 2 FLT3 Inhibitors), $Million, 2021-2032
Figure 46: Global FLT3 Inhibitors Market (by Potential Pipeline Products), $Million, 2021-2032
Figure 47: Global FLT3 Inhibitors Market (Crenolanib), $Million, 2021-2032
Figure 48: Crenolanib Phase III Clinical Trial Design for Newly Diagnosed FLT3 Mutated AML
Figure 49: Crenolanib Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML
Figure 50: Global FLT3 Inhibitors Market (Dovitinib), $Million, 2021-2032
Figure 51: Dovitinib Phase III Clinical Trial Design for Metastatic Renal Cell Carcinoma
Figure 52: Global FLT3 Inhibitors Market (SKLB1028), $Million, 2021-2032
Figure 53: SKLB1028 Phase III Clinical Trial Design for Relapsed/Refractory FLT3 Mutated AML
Figure 54: Global FLT3 Inhibitors Market (by Region), $Million, 2021-2032
Figure 55: North America FLT3 Inhibitors Market, $Million, 2021-2032
Figure 56: North America: Market Dynamics
Figure 57: North America FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
Figure 58: U.S. FLT3 Inhibitors Market, $Million, 2021-2032
Figure 59: Canada FLT3 Inhibitors Market, $Million, 2021-2032
Figure 60: Europe FLT3 Inhibitors Market, $Million, 2021-2032
Figure 61: Europe: Market Dynamics
Figure 62: Europe FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
Figure 63: Germany FLT3 Inhibitors Market, $Million, 2021-2032
Figure 64: Italy FLT3 Inhibitors Market, $Million, 2021-2032
Figure 65: France FLT3 Inhibitors Market, $Million, 2021-2032
Figure 66: U.K. FLT3 Inhibitors Market, $Million, 2021-2032
Figure 67: Spain FLT3 Inhibitors Market, $Million, 2021-2032
Figure 68: Rest-of-Europe FLT3 Inhibitors Market, $Million, 2021-2032
Figure 69: Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032
Figure 70: Asia-Pacific: Market Dynamics
Figure 71: Asia-Pacific FLT3 Inhibitors Market (by Country), $Million, 2021 and 2032
Figure 72: Japan FLT3 Inhibitors Market, $Million, 2021-2032
Figure 73: China FLT3 Inhibitors Market, $Million, 2021-2032
Figure 74: Rest-of-Asia-Pacific FLT3 Inhibitors Market, $Million, 2021-2032
Figure 75: Rest-of-the-World FLT3 Inhibitors Market, $Million, 2021-2032
Figure 76: Total Number of Companies Profiled
Figure 77: Cullinan Oncology, LLC: Pre-Clinical and Clinical Assets
Figure 78: Cullinan Oncology, LLC: R&D Expenditure, $Million, 2019-2021
Figure 79: Astellas Pharma Inc.: Commercialized Product
Figure 80: Astellas Pharma Inc.: Overall Financials, $Million, 2019-2021
Figure 81: Astellas Pharma Inc.: Revenue (by Region), $Million, 2019-2021
Figure 82: Astellas Pharma Inc.: R&D Expenditure, $Million, 2019-2021
Figure 83: Allarity Therapeutics, Inc.: Pre-Clinical and Clinical Assets
Figure 84: AROG Pharmaceuticals, Inc.: Pre-Clinical and Clinical Assets
Figure 85: Aptose Biosciences Inc.: Pre-Clinical and Clinical Assets
Figure 86: Aptose Biosciences Inc.: R&D Expenditure, $Million, 2019-2021
Figure 87: Novartis International AG: Commercialized Product
Figure 88: Novartis International AG: Overall Financials, $Million, 2019-2021
Figure 89: Novartis International AG: Revenue (by Segment), $Million, 2019-2021
Figure 90: Novartis International AG: Revenue (by Region), $Million, 2019-2021
Figure 91: Novartis International AG: R&D Expenditure, $Million, 2019-2021
Figure 92: Daiichi Sankyo Company, Limited: Commercialized Product
Figure 93: Daiichi Sankyo Company, Limited.: Overall Financials, $Million, 2019-2021
Figure 94: Daiichi Sankyo Company, Limited.: Revenue (by Segment), $Million, 2019-2021
Figure 95: Daiichi Sankyo Company, Limited.: Revenue (by Region), $Million, 2019-2021
Figure 96: Daiichi Sankyo Company, Limited.: R&D Expenditure, $Million, 2019-2021
Figure 97: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Pre-Clinical and Clinical Assets
Figure 98: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 99: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Segment), $Million, 2019-2021
Figure 100: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: Revenue (by Region), $Million, 2019-2021
Figure 101: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 102: FUJIFILM Pharmaceuticals U.S.A., Inc.: Pre-Clinical and Clinical Assets
Figure 103: Jiangsu HengRui Medicine Co., Ltd.: Pre-Clinical and Clinical Assets
Figure 104: Jiangsu HengRui Medicine Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 105: Jiangsu HengRui Medicine Co., Ltd.: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Mechanisms of Resistance of FLT3-Mutated AML Cells to FLT3 Inhibitors
Table 2: Prominent CDx Tests for FLT3 Mutated AML
Table 3: Emerging Phase III FLT3 Therapeutics Pipeline
Table 4: Annual Cost of Approved FLT3 Inhibitors in the U.S.
Table 5: Reimbursement Scenario of Approved FLT3 Inhibitors in the U.S.
Table 6: Likert Scale
Table 7: Impact Analysis of Market Drivers
Table 8: Impact Analysis of Market Restraints
Table 9: Approved FLT3 Inhibitors for FLT3 Mutated AML
Table 10: Approved FLT3 Inhibitors Products in Developed Nations
Table 11: Commercialized Products in the Global FLT3 Inhibitors Market
Table 12: Potential Pipeline Products to Global FLT3 Inhibitors Market
Table 13: List of Selective Commercialized FLT3 Inhibitors in the U.S.
Table 14: List of Selective Commercialized FLT3 Inhibitors in Canada
Table 15: List of Selective Commercialized FLT3 Inhibitors in Europe
Table 16: List of Selective Commercialized FLT3 Inhibitors in Japan
Table 17: List of Selective Commercialized FLT3 Inhibitors in China
